Use of any live vaccines (eg, intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TYa typhoid vaccines) within  days
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGuerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Receipt of a live vaccine within  days prior to starting study drug; examples of live vaccines are: intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella, and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGuerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGuerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with pegylated interferon; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Taking any of the following agents:\r\n* Chronic treatment with systemic steroids or another immunosuppressive agent (use of steroids as part of management of everolimus toxicities will be allowed)\r\n* Live vaccines\r\n* Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus CalmetteGurin (BCG), yellow fever, varicella and TYa typhoid vaccines\r\n* Drugs or substances known to be inhibitors or inducers of the isoenzyme cytochrome P family , subfamily A, polypeptide  (CYPA)
Patients should not receive immunization with attenuated live vaccines within one week of starting study drug or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGurin (BCG), yellow fever, varicella and typhoid vaccine live oral (TY)a typhoid vaccines
Patients should not receive immunization with attenuated live vaccines during study period or within  week of study entry; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of study drug and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who plan to receive live attenuated vaccines within  week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TYa typhoid vaccines.
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus. Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus calmette-guerin (BCG), yellow fever, varicella and TYa typhoid vaccines.
Received live attenuated vaccine within  week of start of everolimus (i.e. intranasal influenza, measles, mumps, rubella, oral polio, Bacille de Calmette et Guerin [BCG], yellow fever, varicella, and typhoid vaccine live oral [TYa] typhoid vaccines)
Patients who have received live attenuated vaccines =<  week prior to registration and during the study; note: patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG (bacillus Calmette-Guerin), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus, or have plans to receive such vaccination while on protocol treatment; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGuerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated liver vaccines within one week of study entry or during study period; close contact with those who have received attenuated liver vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Participants who have received immunizations with attenuated live vaccines within one week of study entry are not eligible; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received attenuated live vaccines within one week of study entry; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin [BCG], yellow fever, varicella, and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within  week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacille Calmette Guerin (BCG), yellow fever, varicella, and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines during study period or within  week of study entry; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacille Calmette-Guerin (BCG), yellow fever, varicella, and TYa typhoid vaccines
EXPANSION COHORT ONLY: Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacille Calmette-Guerin (BCG), yellow fever, varicella, and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGurin (BCG), yellow fever, varicella and typhoid (TY)a typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Received immunization with attenuated live vaccines =<  days prior to study entry or during study period; NOTE: Close contact with those who have received attenuated live vaccines should be avoided during treatment with sirolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus CalmetteGurin (BCG), yellow fever, varicella and typhoid (TY)a typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Planned immunization with attenuated live vaccines =< days prior to registration or during study period; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacille Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines during study period or within  week of study entry; close contact with those who have received attenuated live vaccines should be avoided during treatment with RAD; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period; close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Gurin (BCG), yellow fever, varicella and TYa typhoid vaccines
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TYa typhoid vaccines;
